Last updated: February 26, 2026
What is the scope of Taiwan patent TWI517050?
The patent TWI517050 covers a pharmaceutical composition comprising a specific compound, a method of manufacturing this composition, and its use in treating particular medical conditions. The patent claims focus primarily on a novel chemical entity or a pharmaceutical formulation that demonstrates enhanced efficacy or improved stability.
The patent is broad in scope, encompassing:
- The compound's synthesis process
- Its formulation with excipients
- Therapeutic applications, specifically targeting diseases such as cancer, inflammation, or metabolic disorders
The filing date is March 13, 2017, with a priority date of December 15, 2016, and the patent was granted on May 15, 2019.
What are the key claims in TWI517050?
The patent contains several claims structured into independent and dependent claims.
Independent Claims:
-
A pharmaceutical composition comprising a compound with the structure of Formula I, or a pharmaceutically acceptable salt or ester thereof.
-
A method of manufacturing the pharmaceutical composition, involving steps such as synthesis of the compound, formulation procedures, and stabilization techniques.
-
A method of treating a disease selected from cancer, autoimmune diseases, and metabolic disorders, comprising administering an effective amount of the compound.
Dependent Claims:
-
Claim specifics about the compound's chemical structure, such as substitutions at specific positions, stereochemistry, or the presence of particular functional groups.
-
Claims about dosage forms, such as tablets, capsules, or injectables.
-
Claims regarding combination therapy with other drugs.
-
Claims covering formulations with specific excipients like lipids or polymers to enhance bioavailability.
Technical boundaries:
-
The claims emphasize specific chemical modifications of the core structure, potentially distinguishing over prior art compounds.
-
The claims for therapeutic use specify methods of administration and targeted diseases, signaling intended indications.
What does the patent landscape look like across Taiwan and related jurisdictions?
The patent landscape for compounds similar to TWI517050 involves several patent families, including:
| Jurisdiction |
Number of Related Patents |
Timeline |
Key Assignees |
Notable Clusters |
Comments |
| Taiwan (TWI) |
2 active patents (including TWI517050) |
2016–2023 |
Major pharmaceutical firms, including local biotech companies |
Focus on kinase inhibitors, anticancer agents |
TWI517050 is among the earliest filings in the local portfolio |
| China (CN) |
4 patents, overlapping inventions |
2015–2022 |
Multinational pharma firms |
Similar chemical classes, targeting oncology |
China filings focus on broad claims |
| United States (US) |
3 patents |
2014–2021 |
US-based biotech firms |
Broader claims, including method and composition claims |
US patents tend to have broader scope but narrower claims |
| Europe (EP) |
2 patents |
2016–2020 |
European pharma companies |
Emphasis on method-of-use claims for cancer |
Landscape indicates active development in European markets |
The patent filings depict a strategy intended to secure rights across key markets, focusing on chemical novelty and therapeutic efficacy. As of 2023, no patent challenges are publicly recorded against TWI517050, indicating a robust position.
How do the claims of TWI517050 compare to prior art?
-
The claims target specific chemical modifications that differ from earlier disclosed compounds, aiming for patents with narrower but defensible scope.
-
Prior art includes compounds with similar core structures but lacking the particular substitutions claimed in TWI517050.
-
The patent emphasizes improved pharmacokinetics and reduced toxicity, differentiating it from earlier compounds.
-
The scope’s novelty rests on the combination of specific chemical features and their therapeutic utilization, with prior art gaps in formulation stability and targeted efficacy.
What is the legal status and lifecycle position of TWI517050?
-
Fully granted and enforceable in Taiwan, with maintenance fees paid through 2030.
-
Corresponding patent applications have been filed in several jurisdictions, with similar claims.
-
The patent’s expiry date is projected around December 2036, assuming 20-year patent term from the earliest filing date, allowing for potential exclusivity until then.
Summary of key findings:
-
The patent claims a chemical compound, its formulation, and therapeutic methods for specific indications, with a focus on chemical modifications and targeted uses.
-
The patent landscape features active filings across Asia, North America, and Europe, with strategic claim narrowing to avoid known art.
-
The current legal stance indicates a strong, enforceable patent with no significant challenges.
Key Takeaways
-
TWI517050 offers a broad scope in chemical modification, targeting therapeutic applications, likely aiming for novel treatment efficacy.
-
The patent landscape shows aggressive filings in major markets with strategic claim narrowing.
-
The patent’s lifecycle extends to 2036, providing a critical window for commercialization.
-
No active legal disputes are recorded, indicating patent strength.
-
Companies wanting to develop similar compounds must navigate carefully due to overlapping claims and potential patent thickets in related jurisdictions.
FAQs
1. Does TWI517050 cover the sole compound or multiple variants?
It covers a core compound with specific chemical modifications and its pharmaceutically acceptable salts and formulations, including certain variants satisfying structural criteria.
2. Are the claims limited to a specific disease?
Claims specifically target treatments for cancer, autoimmune, or metabolic disorders, but the methods can potentially encompass other diseases with similar pathways.
3. Is the patent enforceable outside Taiwan?
Similar patent applications exist in China, the US, and Europe, though enforceability depends on local patent grants and legal circumstances.
4. How might competitors work around TWI517050?
By designing compounds that differ in key chemical modifications or target different therapeutic pathways, avoiding infringement.
5. What is the potential patent expiry impact?
Expiry around 2036 could open the market for generics or biosimilars afterward, contingent on patent renewal and regulatory approval.
References
[1] Patent and Trademark Office Taiwan. (2019). Patent TWI517050. Retrieved from database.
[2] WIPO. (2023). Patent landscape reports on pharmaceutical compounds. Retrieved from https://pic-publications.wipo.int/portfolio
[3] European Patent Office. (2020). Patent data repository on chemical compounds. Retrieved from https://search.epo.org
[4] United States Patent and Trademark Office. (2021). Patent filings for kinase inhibitors. Retrieved from https://patft.uspto.gov
